Cloud-Clone-supported study finds new endothelial subtype in human coronary atherosclerosis

A Nature Cell Biology study from Fuwai Hospital identified a disease-driving endothelial cell subtype in human coronary arteries and linked it to plaque progression. The research also validated circulating OGN as a potential serum biomarker for coronary atherosclerosis, with Cloud-Clone’s ELISA kit supporting the protein measurements.

Why it matters: - Coronary atherosclerosis remains a leading cause of myocardial infarction and sudden cardiac death. - The study points to a human-specific disease mechanism that could improve how researchers understand plaque growth and how clinicians may one day assess risk. - The work also advances a non-invasive blood biomarker for measuring coronary atherosclerotic burden.

What happened: - Researchers from Fuwai Hospital published Single-cell transcriptomics uncovers endothelial progenitor-like remodelling driving human coronary atherosclerosis progression in Nature Cell Biology in July 2026. - The team analyzed 56 human coronary artery specimens from 19 heart-transplant donors. - The samples were grouped as normal, early-stage atherosclerosis and advanced-stage atherosclerosis. - Single-cell RNA sequencing captured 27,941 high-quality cells. - The dataset identified 9 major cell classes and 37 vascular and immune cell subsets. - Cloud-Clone’s USEC688Hu Human Osteoglycin (OGN) ELISA Kit supported the serum protein measurements used in the biomarker validation work.

The details: - The study identified a new endothelial subset called EC5 SLCO4A1+. - EC5 SLCO4A1+ showed progenitor-like transcriptional signatures and increased in proportion as atherosclerosis progressed. - The subset reduced canonical endothelial-barrier genes and gained stronger migratory and angiogenic behavior. - Those changes weakened vascular barrier integrity and may help lipid and immune-cell infiltration into the intima. - The study found PRDM15 as the key transcription factor driving the EC5 program. - CUT&Tag data showed PRDM15 directly binds genomic loci that activate SLCO4A1 and other EC5-associated genes. - Endothelial-specific Prdm15 overexpression in ApoE-/- mice increased aortic and coronary plaque size, expanded necrotic cores, increased macrophage infiltration and reduced plaque stability. - Endothelial-specific Prdm15 deletion reduced lesion burden, thickened fibrous caps, improved plaque stability and lowered EC5-like pathological endothelial cells. - Cell-communication analysis found a pro-inflammatory feedback loop between EC5 cells and macrophages. - EC5 cells secreted CXCL9, while a pro-inflammatory macrophage subset, MP2, expressed CCL3. - That CXCL9-CCL3 axis appeared to reinforce macrophage recruitment and endothelial reprogramming inside plaques. - The biomarker screen began with 25 altered secreted ligand candidates from single-cell profiling. - The clinical validation cohort included 148 patients undergoing coronary CTA. - Serum osteoglycin, or OGN, correlated positively with coronary artery calcification score. - The finding suggests circulating OGN may reflect total coronary atherosclerotic burden.

Between the lines: - The study is notable because it moves beyond mouse-only models and uses staged human coronary tissue, which can reveal disease biology that animal systems may miss. - The EC5 subtype and PRDM15 axis suggest a more specific target for understanding how endothelial dysfunction becomes a plaque-driving process. - The OGN result is especially relevant because current imaging-based coronary assessment is costly and involves radiation exposure. - The biomarker signal still needs larger cohorts before it can be considered clinically ready.

What's next: - Researchers are likely to test whether PRDM15 or the CXCL9-CCL3 loop can be targeted to slow plaque progression. - Larger patient cohorts will be needed to confirm whether circulating OGN predicts atherosclerotic burden and major cardiovascular outcomes. - Future studies may combine OGN with other markers to improve screening and longitudinal monitoring. - The publicly released single-cell dataset may be mined for additional therapeutic targets and secreted biomarkers.

The bottom line: - The Fuwai Hospital study identifies a previously unknown endothelial cell state linked to human coronary plaque growth and supports OGN as a promising blood-based biomarker for coronary atherosclerosis.